ASH 2023 | Using MRD to understand the response to autoSCT in patients with multiple myeloma
Susan Bal, MD, MBBS, University of Alabama at Birmingham, Birmingham, AL, discusses the use of measurable residual disease (MRD) prior to and following autologous stem cell transplantation (autoSCT) to understand and quantify the depth of response with this intervention in patients with multiple myeloma (MM). Dr Bal highlights that patients with high-risk cytogenetics appear to derive the greatest benefit from autoSCT and comments on whether receiving CD38 monoclonal antibodies or melphalan in induction affects the response to transplantation. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, AbbVie, Janssen, Astrazeneca, Adaptive Biotechnologies
Honoraria: BMS, AbbVie, Janssen, Astrazeneca, Adaptive Biotechnologies, MJH Life Sciences
Research Funding: BMS, Adaptive Biotechnologies, Amyloid Foundation, BeiGene, Fate Therapeutics
Educational Content Development: MJH Life Sciences
